Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Louise Kathleen Kostos"'
Autor:
Louise Kathleen Kostos, James Patrick Buteau, Grace Kong, Theresa Yeung, Juliana Di Iulio, Michael T Fahey, Heidi Fettke, Luc Furic, Michael S Hofman, Arun Azad
Publikováno v:
Journal of Clinical Oncology. 41:TPS278-TPS278
TPS278 Background: [177Lu]Lu-PSMA-617 was recently FDA-approved for use in the post-taxane, post-antiandrogen setting in pts with mCRPC. Despite conferring a survival benefit, for many the treatment response is short, and progression is inevitable. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4e9d274d61ff77e509e45383c027fd1
https://doi.org/10.1200/jco.2023.41.6_suppl.tps278
https://doi.org/10.1200/jco.2023.41.6_suppl.tps278
Autor:
James Patrick Buteau, Louise Kathleen Kostos, Ramin Alipour, Price Jackson, Lachlan McIntosh, Brittany Emmerson, Mohammad B Haskali, Theresa Yeung, Sophia Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Nicole Ng, Maria Docanto, Patricia Bukczynska, Benjamin Blyth, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS281-TPS281
TPS281 Background: [177Lu]Lu-PSMA is an effective class of therapy for men with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response is partially explained by the presence of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c98f01a7d11553724c3c6c8b56e88af
https://doi.org/10.1200/jco.2023.41.6_suppl.tps281
https://doi.org/10.1200/jco.2023.41.6_suppl.tps281
Autor:
Louise Kathleen Kostos, William Yu Ching Lai, Peter Lambroglou, Elizabeth Medhurst, James Patrick Buteau, Shahneen Sandhu, Ben Tran, Lavinia Anne Spain, Ciara Conduit, Roslyn Wallace, Ramin Alipour, Timothy J. Akhurst, Grace Kong, Anthony Cardin, Javad Saghebi, Aravind Ravi Kumar, Michael S Hofman, Arun Azad
Publikováno v:
Journal of Clinical Oncology. 41:77-77
77 Background: [177Lu]Lu-PSMA (LuPSMA) is currently FDA-approved for use in the post-taxane, post-antiandrogen setting in pts with mCRPC. Little is known about the efficacy of treatment in pts with subsequent progression after LuPSMA. In this single-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c857bd4c6a9a327b50ded5ac6f25112e
https://doi.org/10.1200/jco.2023.41.6_suppl.77
https://doi.org/10.1200/jco.2023.41.6_suppl.77
Autor:
Louise Kathleen Kostos, James Patrick Buteau, Theresa Yeung, Sophia Xie, Juliana Di Iulio, Anthony Cardin, Katie Owen, Heidi Fettke, Kwang Y Chin, Brittany Emmerson, Mohammad B Haskali, Belinda Parker, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS280-TPS280
TPS280 Background: [177Lu]Lu-PSMA-I&T (LuPSMA) is a small molecule radioligand that delivers radiation via beta-particulate emission to cells expressing prostate-specific membrane antigen (PSMA). Despite a survival benefit in mCRPC, responses for man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c858b31d10f3d96b1323f320d58d3920
https://doi.org/10.1200/jco.2023.41.6_suppl.tps280
https://doi.org/10.1200/jco.2023.41.6_suppl.tps280